Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells.
Rhabdomyosarcoma is the most common soft tissue sarcoma in the pediatric population. As this tumor has an undifferentiated myogenic phenotype, agents that promote differentiation hold particular promise as part of a novel therapeutic approach to combat this type of cancer. In this report, we focus on the contribution of two microRNAs (miRNAs) in rhabdomyosarcomas. Levels of miR-1 and miR-133a are drastically reduced in representative cell lines from each major rhabdomyosarcoma subtype (embryonal and alveolar). Introduction of miR-1 and miR-133a into an embryonal rhabdomyosarcoma-derived cell line is cytostatic, thereby suggesting a tumor suppressor-like role for these myogenic miRNAs. Transcriptional profiling of cells after miR-1 and miR-133a expression reveals that miR-1 (but not miR-133a) exerts a strong promyogenic influence on these poorly differentiated tumor cells. We identify mRNAs that are down-regulated by these miRNAs and propose roles for miR-1 and miR-133a in repressing isoforms of genes that are normally not expressed in muscle. Finally, we show that mRNA targets of miR-1 and miR-133a are up-regulated in rhabdomyosarcomas, suggesting a causative role for these miRNAs in the development of rhabdomyosarcomas. More important, these results point to the promise of enhancing rhabdomyosarcoma therapy using miRNAs as agents that mediate cytostasis and promote muscle differentiation.
Rao
Prakash K
PK
Whitehead Institute for Biomedical Research, 9 Cambridge Center, Cambridge, MA 02142, USA.
Missiaglia
Edoardo
E
Shields
Lauren
L
Hyde
Greg
G
Yuan
Bingbing
B
Shepherd
Christopher J
CJ
Shipley
Janet
J
Lodish
Harvey F
HF
D002454:Cell Differentiation / Q000235:genetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D020869:Gene Expression Profiling; D006801:Humans; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D012208:Rhabdomyosarcoma / Q000235:genetics* / Q000473:pathology*
D035683:MicroRNAs
Science. 2005 Jul 8;309(5732):310-1
15919954
Genes Dev. 2005 Mar 1;19(5):553-69
15706034
Curr Biol. 2002 Apr 30;12(9):735-9
12007417
J Biol Chem. 2000 Jan 7;275(1):41-6
10617583
Pathol Int. 2006 May;56(5):246-55
16669873
Genome Biol. 2003;4(5):P3
12734009
Genes Dev. 2009 Mar 1;23(5):619-32
19240126
Cancer. 1958 Jan-Feb;11(1):181-99
13500314
Genes Chromosomes Cancer. 2009 Jun;48(6):455-67
19235922
Cell. 2009 Jan 23;136(2):215-33
19167326
Dev Biol. 2007 Nov 15;311(2):359-68
17936265
Cancer Cell. 2008 Nov 4;14(5):369-81
18977326
Cell. 2004 Jan 23;116(2):281-97
14744438
Genome Biol. 2004;5(3):R13
15003116
Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8721-6
16731620
Nat Protoc. 2009;4(1):44-57
19131956
J Clin Invest. 2009 Aug;119(8):2366-78
19620785
Am J Surg Pathol. 2006 Aug;30(8):962-8
16861966
Mol Biol Cell. 2009 Feb;20(4):1120-31
19109424
J Biol Chem. 2009 Oct 23;284(43):29596-604
19710019
Exp Cell Res. 1993 Sep;208(1):209-17
8395398
Oncogene. 2008 Nov 20;27(51):6550-60
18679424
Mol Cell Biol. 1995 Mar;15(3):1522-35
7862145
Nat Genet. 2001 Feb;27(2):187-90
11175787
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20844-9
18093911
RNA. 2005 Mar;11(3):241-7
15701730
Blood. 2008 Mar 1;111(5):2505-15
18299451
J Biol Chem. 2001 Nov 2;276(44):41486-91
11522799
Cell. 2005 Jan 14;120(1):15-20
15652477
Oncogene. 1999 Sep 20;18(38):5340-8
10498887
Nature. 2005 Jul 14;436(7048):214-20
15951802
Mol Cell. 2000 Aug;6(2):233-44
10983972
Cell. 2003 Dec 26;115(7):787-98
14697198
Genes Chromosomes Cancer. 1999 Dec;26(4):275-85
10534762
Oncogene. 2008 Mar 27;27(14):2015-26
17922033
Cell. 2005 Dec 16;123(6):1133-46
16337999
Nat Genet. 2006 Feb;38(2):228-33
16380711
Cancer Res. 2006 Jul 15;66(14):6936-46
16849537
Development. 2001 Nov;128(22):4623-33
11714687